Table 1. Studies of anti–PD-1 or PD-L1... | American Society of Hematology

Table 1.

Studies of anti–PD-1 or PD-L1 antibody monotherapy in rel/ref HL

Drug	Phase	N	ORR, %	CR, %	DOR	Median PFS, unless specified	Reference
Nivolumab	1	23	87	17	*	86% at 24 wk	8
Nivolumab	2						10
Overall		243	69	16	16.6 mo	14.7 mo
Cohort A		63	65	29	20.3 mo	18.3 mo
Cohort B		80	68	13	15.9 mo	14.7 mo
Cohort C		100	73	12	14.5 mo	11.9 mo
Pembroliuzmab	1	31	65	16	70% with DOR ≥24 wk	46% at 52 wk	11
Pembroliuzmab	2						12
Overall		210	69	22	Not reached	63% at 9 mo
Cohort A		69	74	22	Not reached
Cohort B		81	64	25	Not reached
Cohort C		60	70	20	Not reached
Avelumab	1	31	42	16	*	*	13

Drug	Phase	N	ORR, %	CR, %	DOR	Median PFS, unless specified	Reference
Nivolumab	1	23	87	17	*	86% at 24 wk	8
Nivolumab	2						10
Overall		243	69	16	16.6 mo	14.7 mo
Cohort A		63	65	29	20.3 mo	18.3 mo
Cohort B		80	68	13	15.9 mo	14.7 mo
Cohort C		100	73	12	14.5 mo	11.9 mo
Pembroliuzmab	1	31	65	16	70% with DOR ≥24 wk	46% at 52 wk	11
Pembroliuzmab	2						12
Overall		210	69	22	Not reached	63% at 9 mo
Cohort A		69	74	22	Not reached
Cohort B		81	64	25	Not reached
Cohort C		60	70	20	Not reached
Avelumab	1	31	42	16	*	*	13

Not reported.